The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a wave of positive recommendations for new medicines, according to a report from Fierce Pharma. The endorsements cover a range of therapies and include notable products from Novo Nordisk and AstraZeneca.
Among the highlighted decisions was a positive opinion for Novo Nordisk's next-generation treatment for hemophilia A. The therapy is designed to offer a new option for patients with the bleeding disorder, though the source does not provide specific efficacy or safety details.
AstraZeneca also had new offerings backed by the committee, according to the report. The CHMP's recommendations are typically followed by formal approval from the European Commission, which grants marketing authorization across the EU.